UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 71-0869350 (State or Other Jurisdicti ...

| --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 40th Annual J.P. Morgan Healthcare Conference | | | | | | | | | At the Forefront of Therapies | | | | | | | | | January 12, 2022 for Rare Diseases | | | | | | | | 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Priva ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2021 Earnings Conference Call November 9, 2021 8:30 AM ET Company Participants Andrew Faughnan – Head-Investor Relations John Crowley – Chairman and Chief Executive Officer Bradley Campbell – President and Chief Operating Officer Jeff Castelli – Chief Development Officer Daphne Quimi – Chief Financial Officer Conference Call Participants Anvita Gupta – Cowen Anupam Rama – JPMorgan Joseph Schwartz – SVB Leerink Dae Gon Ha – Stifel Yun Zhong – BTIG Nishant Gandhi – N ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of (I.R. ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Formation of Caritas Therapeutics Conference Call September 29, 2021 8:00 AM ET Company Participants Andrew Faughnan - Executive Director, IR John F. Crowley - Chairman and CEO Bradley L. Campbell - President and COO Daphne Quimi - CFO Conference Call Participants Ritu Baral - Cowen Tazeen Ahmad - Bank of America Merrill Lynch Eliana Merle - UBS Investment Bank Anupam Rama - JP Morgan Elizabeth Webster - Goldman Sachs Joseph Schwartz - SVB Leerink Dae Gon Ha - Stifel, ...

Amicus Launches Next-Generation Genetic Medicine Company Conference Call & Webcast September 29, 2021 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business combination, development of Caritas' product candidates, preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2021 Earnings Conference Call August 5, 2021 8:00 AM ET Company Participants Andrew Faughnan - Head, Investor Relations John Crowley - Chairman and Chief Executive Officer Bradley Campbell - President and Chief Operating Officer Daphne Quimi - Chief Financial Officer Jeff Castelli - Chief Development Officer Mitchell Goldman - Chief Medical Officer Conference Call Participants Ritu Baral - Cowen Ellie Merle - UBS Kristen Kluska - Cantor Fitzgerald Anupam Rama - JPM ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33497 Amicus Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of (I.R.S. Em ...

General Corporate & Gene Therapy Overview: At the Forefront of the Human Genome Medicine Revolution May 2021 General Corporate & Gene Therapy Overview Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential reg ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2021 Earnings Conference Call May 10, 2021 8:30 AM ET Company Participants Andrew Faughnan - Head, IR John Crowley - Chairman and CEO Bradley Campbell - President and COO Daphne Quimi - CFO Jeff Castelli - Chief Development Officer Mitchell Goldman - SVP, Clinical Research Conference Call Participants Ritu Baral - Cowen & Company Tazeen Ahmad - Bank of America Kristen Kluska - Cantor Fitzgerald Tessa Romero - JPMorgan Salveen Richter - Goldman Sachs Mohit Bansal - ...